CD109 and neoplasm: To investigate the role of CD109 in tumor initiation and progression in vivo, we analyzed the development of intracranial xenografts derived from control and CD109-silenced GSCs using 4 different sets of GSCs initially enriched with either the MES- or PN-like signature.